| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1C at Week 54, Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C., Baseline and Week 54|Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue, An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure., Up to Week 57|Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue, Up to Week 54 | Secondary: Change From Baseline in Fasting Plasma Glucose at Week 54, Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline)., Baseline and Week 54|Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54, The percentage of participants who achieved A1C values \<6.5% (48 mmol/mol) in the FAS Population at Week 54., Week 54|Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue, Symptomatic episode of hypoglycemia was an episode with clinical symptoms reported by the investigator as hypoglycemia (concurrent fingerstick glucose not required)., Up to Week 54|Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue, Baseline and Week 54|Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54, The percentage of participants who achieved A1C values \<7.0% (53 mmol/mol) in the FAS Population at Week 54., Week 54
|
